Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.11 USD | +1.10% | -3.01% | +17.86% |
Financials (USD)
Sales 2024 * | 603M | Sales 2025 * | 622M | Capitalization | 1.87B |
---|---|---|---|---|---|
Net income 2024 * | 14M | Net income 2025 * | 5M | EV / Sales 2024 * | 3.1 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3 x |
P/E ratio 2024 * |
620
x | P/E ratio 2025 * |
341
x | Employees | 652 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.88% |
Latest transcript on Supernus Pharmaceuticals, Inc.
1 day | +1.10% | ||
1 week | -3.01% | ||
Current month | +14.85% | ||
1 month | +9.75% | ||
3 months | +15.90% | ||
6 months | +21.47% | ||
Current year | +17.86% |
Managers | Title | Age | Since |
---|---|---|---|
Jack Khattar
FOU | Founder | 62 | 05-03-29 |
Timothy Dec
DFI | Director of Finance/CFO | 66 | 21-08-22 |
Frank Mottola
CTO | Chief Tech/Sci/R&D Officer | 52 | 04-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Georges Gemayel
BRD | Director/Board Member | 64 | 15-03-22 |
Charles Newhall
CHM | Chairman | 79 | 05-03-29 |
John Siebert
BRD | Director/Board Member | 84 | 10-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.94% | 29 M€ | +0.33% | ||
0.94% | 17 M€ | -0.46% | ||
0.38% | 26 M€ | +0.78% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 34.11 | +1.10% | 491,007 |
24-03-27 | 33.74 | +3.88% | 363,964 |
24-03-26 | 32.48 | -0.82% | 611,763 |
24-03-25 | 32.75 | -5.13% | 366,595 |
24-03-22 | 34.52 | -1.85% | 492,786 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.86% | 1.87B | |
+13.52% | 9.63B | |
-7.87% | 5.37B | |
+12.50% | 4.28B | |
+18.09% | 3.71B | |
+42.95% | 2.91B | |
-19.01% | 2.54B | |
-20.66% | 2.37B | |
-0.50% | 1.64B | |
-8.99% | 1.65B |